title: Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.
abstract: The mechanisms underlying adjuvant effects are under renewed scrutiny because of the enormous implications for vaccine development. Additionally, new low-toxicity adjuvants are sought to enhance vaccine formulations. Muramyl dipeptide (MDP) is a component of the peptidoglycan polymer and was shown to be an active but low-toxicity component of complete Freund's adjuvant, a powerful adjuvant composed of mycobacteria lysates in an oil emulsion. MDP activates cells primarily via the cytosolic NLR family member Nod2 and is therefore linked to the ability of adjuvants to enhance antibody production. Accordingly, we tested the adjuvant properties of the MDP-Nod2 pathway. We found that MDP, compared to the TLR agonist lipopolysaccharide, has minimal adjuvant properties for antibody production under a variety of immunization conditions. We also observed that the oil emulsion incomplete Freund's adjuvant (IFA) supplanted the requirements for the TLR pathway independent of the antigen. Surprisingly, we observed that Nod2 was required for an optimal IgG1 and IgG2c response in the absence of exogenous TLR or NLR agonists. Collectively, our results argue that oil emulsions deserve greater attention for their immunostimulatory properties.
authors.affiliation: Department of Infectious Diseases, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
authors.forename: Lilian O
authors.initials: LO
authors.lastname: Moreira
authors.forename: Amber M
authors.initials: AM
authors.lastname: Smith
authors.forename: Ashley A
authors.initials: AA
authors.lastname: DeFreitas
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Qualls
authors.forename: Karim C
authors.initials: KC
authors.lastname: El Kasmi
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Murray
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000220:Adaptation, Biological / Q000235:genetics* / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004655:Emulsions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005620:Freund's Adjuvant / Q000494:pharmacology; D007109:Immunity / Q000235:genetics* / Q000276:immunology*; D007114:Immunization; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007274:Injections, Intraperitoneal; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics* / Q000502:physiology*; D012709:Serum Albumin / Q000276:immunology; D051193:Toll-Like Receptors / Q000235:genetics / Q000276:immunology; D032581:Tuberculosis Vaccines / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D004655:Emulsions; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D053594:Myeloid Differentiation Factor 88; D053473:Nod2 Signaling Adaptor Protein; D012709:Serum Albumin; D051193:Toll-Like Receptors; D032581:Tuberculosis Vaccines; D014612:Vaccines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D005620:Freund's Adjuvant
references.citation: J Exp Med. 2008 Apr 14;205(4):869-82
references.pmid: 18362170
references.citation: Mol Cell Biol. 2003 Nov;23(21):7531-9
references.pmid: 14560001
references.citation: Nature. 2007 Jul 26;448(7152):427-34
references.pmid: 17653185
references.citation: J Immunol. 2008 Apr 15;180(8):5402-12
references.pmid: 18390722
references.citation: J Neurochem. 2006 Oct;99(2):596-607
references.pmid: 16879708
references.citation: J Immunol. 2005 Jun 1;174(11):7096-103
references.pmid: 15905553
references.citation: Science. 2007 Jun 15;316(5831):1628-32
references.pmid: 17569868
references.citation: Eur J Immunol. 2008 Aug;38(8):2085-9
references.pmid: 18624356
references.citation: Immunity. 1998 Jul;9(1):143-50
references.pmid: 9697844
references.citation: J Leukoc Biol. 2007 Jul;82(1):177-83
references.pmid: 17403772
references.citation: Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317-25
references.pmid: 4606813
references.citation: N Engl J Med. 1995 May 11;332(19):1280-4
references.pmid: 7708073
references.citation: Vaccine. 1992;10(14):1000-6
references.pmid: 1471423
references.citation: Immunity. 2007 Nov;27(5):687-90
references.pmid: 18031690
references.citation: Mol Cell Biochem. 1981 Dec 4;41:27-47
references.pmid: 7035868
references.citation: Trends Parasitol. 2005 Sep;21(9):412-4
references.pmid: 16043410
references.citation: J Biol Chem. 2002 Oct 18;277(42):39179-86
references.pmid: 12151399
references.citation: Nat Immunol. 2007 Dec;8(12):1269-71
references.pmid: 18026075
references.citation: J Clin Invest. 2007 Mar;117(3):514-21
references.pmid: 17332878
references.citation: Vaccine. 1999 Oct 14;18(5-6):434-9
references.pmid: 10519932
references.citation: Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7803-8
references.pmid: 18511561
references.citation: Nature. 2006 Mar 9;440(7081):228-32
references.pmid: 16407890
references.citation: Curr Opin Immunol. 2005 Aug;17(4):352-8
references.pmid: 15950446
references.citation: Immunity. 2007 Oct;27(4):549-59
references.pmid: 17967410
references.citation: Mol Cell. 2007 Mar 9;25(5):713-24
references.pmid: 17349957
references.citation: J Immunol. 2008 Jul 1;181(1):17-21
references.pmid: 18566365
references.citation: Clin Pharmacol Ther. 2007 Dec;82(6):740-4
references.pmid: 17971820
references.citation: Curr Biol. 2004 Nov 9;14(21):1929-34
references.pmid: 15530394
references.citation: Nature. 2008 Jun 19;453(7198):1122-6
references.pmid: 18496530
references.citation: Am J Physiol. 1988 Jul;255(1 Pt 2):R157-65
references.pmid: 3394839
references.citation: Nat Rev Immunol. 2008 Jun;8(6):458-66
references.pmid: 18500230
references.citation: Biochem Biophys Res Commun. 1974 Feb 4;56(3):561-7
references.pmid: 4597063
references.citation: J Immunol. 2007 Apr 15;178(8):5271-6
references.pmid: 17404311
references.citation: Nat Rev Immunol. 2006 Jan;6(1):9-20
references.pmid: 16493424
references.citation: J Immunol. 2006 Nov 1;177(9):6182-91
references.pmid: 17056547
references.citation: Infect Immun. 1995 Jan;63(1):110-5
references.pmid: 7806345
references.citation: Nature. 2005 Nov 17;438(7066):364-8
references.pmid: 16292312
references.citation: Behav Brain Res. 1995 Jul-Aug;69(1-2):85-90
references.pmid: 7546321
references.citation: Int J Immunopharmacol. 1979;1(1):35-41
references.pmid: 551094
references.citation: Science. 2005 Feb 4;307(5710):731-4
references.pmid: 15692051
references.citation: Science. 2006 Dec 22;314(5807):1936-8
references.pmid: 17185603
references.citation: Curr Opin Immunol. 2007 Jun;19(3):268-74
references.pmid: 17433875
references.citation: PLoS One. 2007 Jun 13;2(6):e523
references.pmid: 17565376
references.citation: Immunology. 1978 Dec;35(6):963-70
references.pmid: 738768